NCT03514407 - A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

June 25, 2020

Study Completion Date

June 25, 2020

Conditions

Relapsed Ewing Sarcoma

Interventions

DRUG

INCB059872

Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.

Trial Locations (11)

10032

Columbia University Medical Center, New York

28040

Hospital Clínico San Carlos, Madrid

32224

Mayo Clinic Jacksonville - PPDS, Jacksonville

38105

St. Jude Children's Research Hospital, Memphis

40136

Istituto Ortopedico Rizzoli, Bologna

40138

Policlinico Sant'orsola-Malpighi, Bologna

77030

MD Anderson Cancer Center, Houston

90095

UCLA Jonsson Comprehensive Cancer, Los Angeles

00146

Ospedale Pediatrico Bambino Gesu IRCCS, Rome

08035

Hospital Universitario Vall d'Hebron, Barcelona

M20 4BX

The Christie NHS Foundation Trust, Manchester